Company Description
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions.
The company’s lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure.
It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions.
The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020.
VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
| Country | United States |
| Founded | 2003 |
| IPO Date | Jan 25, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | David Domzalski |
Contact Details
Address: 685 Route 202/206 N, Suite 301 Bridgewater, New Jersey 08807 United States | |
| Phone | 800 775 7936 |
| Website | vynetherapeutics.com |
Stock Details
| Ticker Symbol | VYNE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001566044 |
| CUSIP Number | 92941V209 |
| ISIN Number | US92941V3087 |
| Employer ID | 45-3757789 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David T. Domzalski | Chief Executive Officer, President and Director |
| Dr. Iain A. Stuart Ph.D. | Chief Scientific Officer |
| Mutya Harsch J.D. | General Counsel, Chief Legal Officer and Company Secretary |
| Tyler Zeronda CPA | Chief Financial Officer and Treasurer |
| Dr. Darrell S. Rigel FAAD, M.D. | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 30, 2025 | 8-K | Current Report |
| May 19, 2025 | SCHEDULE 13G/A | Filing |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| Mar 6, 2025 | 10-K | Annual Report |
| Mar 6, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |
| Dec 23, 2024 | 8-K | Current Report |